

David R Andes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6189406/publications.pdf>

Version: 2024-02-01

222
papers

26,088
citations

10389
72
h-index

6654
156
g-index

241
all docs

241
docs citations

241
times ranked

18474
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome Mining and Metabolomics Unveil Pseudonochelin: A Siderophore Containing 5-Aminosalicylate from a Marine-Derived <i>Pseudonocardia</i> sp. Bacterium. <i>Organic Letters</i> , 2022, 24, 3998-4002.	4.6	7
2	Targeting fungal membrane homeostasis with imidazopyrazoindoles impairs azole resistance and biofilm formation. <i>Nature Communications</i> , 2022, 13, .	12.8	21
3	Novel approaches for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> : Using nanoparticles to overcome multidrug resistance. <i>Drug Discovery Today</i> , 2021, 26, 31-43.	6.4	30
4	The protein kinase Ire1 impacts pathogenicity of <i>Candida albicans</i> by regulating homeostatic adaptation to endoplasmic reticulum stress. <i>Cellular Microbiology</i> , 2021, 23, e13307.	2.1	18
5	A Dual-Responsive Antibiotic-Loaded Nanoparticle Specifically Binds Pathogens and Overcomes Antimicrobial-Resistant Infections. <i>Advanced Materials</i> , 2021, 33, e2006772.	21.0	76
6	Echinocandins. , 2021, , 438-448.		0
7	Chemical Exchanges between Multilateral Symbionts. <i>Organic Letters</i> , 2021, 23, 1648-1652.	4.6	16
8	Formation and characterization of biofilms formed by salt-tolerant yeast strains in seawater-based growth medium. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 2411-2426.	3.6	5
9	Turbinmicin inhibits <i>Candida</i> biofilm growth by disrupting fungal vesicle-mediated trafficking. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	29
10	Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 867-891.	4.7	41
11	The Role of New Posaconazole Formulations in the Treatment of <i>Candida albicans</i> Infections: Data from an <i>In Vitro</i> Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
12	Evolution of the complex transcription network controlling biofilm formation in <i>Candida</i> species. <i>ELife</i> , 2021, 10, .	6.0	25
13	Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 288-296.	3.1	7
14	Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 2256-2264.	1.0	4
15	Regulatory Level of Evidence and Practicality in Antifungal Use Decisions for Less Common Fungal Diseases. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	2
16	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e364-e374.	9.1	99
17	Specialized Metabolites Reveal Evolutionary History and Geographic Dispersion of a Multilateral Symbiosis. <i>ACS Central Science</i> , 2021, 7, 292-299.	11.3	23
18	A small molecule produced by <i>Lactobacillus</i> species blocks <i>Candida albicans</i> filamentation by inhibiting a DYRK1-family kinase. <i>Nature Communications</i> , 2021, 12, 6151.	12.8	50

#	ARTICLE	IF	CITATIONS
19	Coordination of fungal biofilm development by extracellular vesicle cargo. <i>Nature Communications</i> , 2021, 12, 6235.	12.8	42
20	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Pharmaceutics</i> , 2021, 13, 1791.	4.5	9
21	Continuous flow synthesis and antimicrobial evaluation of NHC* silver carboxylate derivatives of SBC3 <i>in vitro</i> and <i>in vivo</i> . <i>Metallomics</i> , 2021, 13, .	2.4	9
22	A Label-Free Cellular Proteomics Approach to Decipher the Antifungal Action of DiMIQ, a Potent Indolo[2,3-b]Quinoline Agent, against <i>Candida albicans</i> Biofilms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 108.	4.1	4
23	Preventing <i>Pseudomonas aeruginosa</i> Biofilms on Indwelling Catheters by Surface-Bound Enzymes. <i>ACS Applied Bio Materials</i> , 2021, 4, 8248-8258.	4.6	16
24	Contributions of Extracellular Vesicles to Fungal Biofilm Pathogenesis. <i>Current Topics in Microbiology and Immunology</i> , 2021, 432, 67-79.	1.1	2
25	Candidemia in the Growing Opioid Epidemic: A Distinct and Emerging Entity. <i>Clinical Infectious Diseases</i> , 2020, 71, 1738-1740.	5.8	1
26	In Vivo Pharmacodynamic Evaluation of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	8
27	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
28	A marine microbiome antifungal targets urgent-threat drug-resistant fungi. <i>Science</i> , 2020, 370, 974-978.	12.6	102
29	Biomaterial armor in leaf-cutter ants. <i>Nature Communications</i> , 2020, 11, 5792.	12.8	34
30	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	4.0	83
31	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3023-3028.	3.0	13
32	Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	24
33	An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen <i>Candida auris</i> . <i>Nature Communications</i> , 2020, 11, 6429.	12.8	49
34	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for <i>Candida albicans</i> Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
35	Pyridine-2,6-Dithiocarboxylic Acid and Its Metal Complexes: New Inhibitors of New Delhi Metallo- β -Lactamase-1. <i>Marine Drugs</i> , 2020, 18, 295.	4.6	1
36	Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa084.	0.9	8

#	ARTICLE	IF	CITATIONS
37	Contributions of the Biofilm Matrix to Candida Pathogenesis. Journal of Fungi (Basel, Switzerland), 2020, 6, 21.	3.5	58
38	A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation. Transplant Infectious Disease, 2019, 21, e13156.	1.7	11
39	The Candida albicans biofilm gene circuit modulated at the chromatin level by a recent molecular histone innovation. PLoS Biology, 2019, 17, e3000422.	5.6	22
40	Characterization of an Uncinocarpus reesii-expressed recombinant tube precipitin antigen of Coccidioides posadasii for serodiagnosis. PLoS ONE, 2019, 14, e0221228.	2.5	4
41	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2019, 74, 3056-3062.	3.0	54
42	Impact of Triazole Therapeutic Drug Monitoring Availability and Timing. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
43	Pyonitrins Aâ€”D: Chimeric Natural Products Produced by <i>Pseudomonas protegens</i>. Journal of the American Chemical Society, 2019, 141, 17098-17101.	13.7	27
44	<i>In vivo</i> pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. Journal of Antimicrobial Chemotherapy, 2019, 74, iii5-iii10.	3.0	20
45	<i>In Vivo</i> Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
46	Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
47	Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis. Journal of Biological Chemistry, 2019, 294, 2700-5412.	3.4	15
48	APX001 Pharmacokinetic/Pharmacodynamic Target Determination against <i>Aspergillus fumigatus</i> in an <i>In Vivo</i> Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	37
49	The antimicrobial potential of Streptomyces from insect microbiomes. Nature Communications, 2019, 10, 516.	12.8	222
50	Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. Infectious Disease Clinics of North America, 2019, 33, 399-445.	5.1	16
51	Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical β -Peptides To Prevent Candida albicans Biofilm Formation. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
52	Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	4
53	<i>In Vivo</i> Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
54	WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo- β -Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17

#	ARTICLE	IF	CITATIONS
55	Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 761-767.	3.0	48
56	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
57	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20
58	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. <i>Clinical Infectious Diseases</i> , 2019, 68, 850-853.	5.8	31
59	Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?. <i>Clinical Infectious Diseases</i> , 2019, 68, 1990-1992.	5.8	4
60	Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm. <i>ISME Journal</i> , 2018, 12, 1427-1442.	9.8	111
61	Pharmacokinetics–pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 371-382.	1.8	8
62	Conservation and Divergence in the <i>Candida</i> Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. <i>MBio</i> , 2018, 9, .	4.1	52
63	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against <i>Candida</i> spp. in a Neutropenic Disseminated Candidiasis Mouse Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	56
64	Identification of the <i>In Vivo</i> Pharmacokinetics and Pharmacodynamic Driver of Iclaprim. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	7
65	We can do better: a fresh look at echinocandin dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, i44-i50.	3.0	37
66	1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against <i>S. aureus</i> (SA) and <i>S. pneumoniae</i> (SPN). <i>Open Forum Infectious Diseases</i> , 2018, 5, S426-S426.	0.9	1
67	<i>Candida</i> –streptococcal interactions in biofilm-associated oral diseases. <i>PLoS Pathogens</i> , 2018, 14, e1007342.	4.7	103
68	<i>Candida albicans</i> biofilm–induced vesicles confer drug resistance through matrix biogenesis. <i>PLoS Biology</i> , 2018, 16, e2006872.	5.6	173
69	Pharmacodynamic Evaluation of Rezafungin (CD101) against <i>Candida auris</i> in the Neutropenic Mouse Invasive Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	56
70	Methodologies for <i>in vitro</i> and <i>in vivo</i> evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. <i>Microbial Cell</i> , 2018, 5, 300-326.	3.2	81
71	<i>In Vivo</i> Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	9
72	Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	94

#	ARTICLE	IF	CITATIONS
73	Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced antifungal activity. <i>Nanomedicine</i> , 2018, 13, 1139-1155.	3.3	36
74	Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	48
75	In Vivo Candida Device Biofilm Models. , 2017, , 93-113.		0
76	<i>In Vivo</i> Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against <i>Streptococcus pneumoniae</i> in the Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	37
77	Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation. <i>Pharmaceutical Research</i> , 2017, 34, 1115-1124.	3.5	12
78	Candida Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms. , 2017, , 77-92.		4
79	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	71
80	<i>In Vivo</i> Pharmacodynamic Target Assessment of Eravacycline against <i>Escherichia coli</i> in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	35
81	The Role of Biofilm Matrix in Mediating Antifungal Resistance. , 2017, , 369-384.		2
82	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	22
83	Pharmacodynamic Optimization for the Treatment of Invasive <i>Candida auris</i> Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, S73-S73.	0.9	1
84	In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. <i>Current Opinion in Pharmacology</i> , 2017, 36, 94-99.	3.5	42
85	Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	26
86	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	75
87	Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in<i> Candida albicans</i>. <i>Cellular Microbiology</i> , 2017, 19, e12767.	2.1	16
88	The Role of In Vitro Susceptibility Testing in the Management of <i>Candida</i> and <i>Aspergillus</i> . <i>Journal of Infectious Diseases</i> , 2017, 216, S452-S457.	4.0	14
89	Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against <i>Candida</i> Species. <i>Open Forum Infectious Diseases</i> , 2017, 4, S298-S298.	0.9	0
90	<i>Candida albicans</i> FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis. <i>PLoS Pathogens</i> , 2017, 13, e1006763.	4.7	57

#	ARTICLE	IF	CITATIONS
91	Traditional PK-PD Indices for Efficacy “Can We Do Better?”. Open Forum Infectious Diseases, 2017, 4, S298-S298.	0.9	3
92	Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	65
93	Bypass of Candida albicans Filamentation/Biofilm Regulators through Diminished Expression of Protein Kinase Cak1. PLoS Genetics, 2016, 12, e1006487.	3.5	39
94	Comparative In Vivo Pharmacokinetics/Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh Infection Model Against Staphylococcus aureus. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
95	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP). Open Forum Infectious Diseases, 2016, 3, .	0.9	1
96	Animal Models to Evaluate Anti-infective Pharmacodynamics. Methods in Pharmacology and Toxicology, 2016, , 59-87.	0.2	2
97	Antifungal Pharmacokinetics and Pharmacodynamics. Methods in Pharmacology and Toxicology, 2016, , 369-383.	0.2	0
98	Pleiotropic effects of the vacuolar ABC transporter MLT1 of Candida albicans on cell function and virulence. Biochemical Journal, 2016, 473, 1537-1552.	3.7	28
99	Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 3398-3406.	3.2	45
100	Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix. MBio, 2016, 7, .	4.1	202
101	Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. Nature Chemical Biology, 2016, 12, 867-875.	8.0	79
102	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorganic and Medicinal Chemistry, 2016, 24, 6390-6400.	3.0	79
103	The epidemiology and outcomes of invasive <i>Candida</i> infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Transplant Infectious Disease, 2016, 18, 921-931.	1.7	135
104	Global Identification of Biofilm-Specific Proteolysis in Candida albicans. MBio, 2016, 7, .	4.1	63
105	Large-scale production and isolation of Candida biofilm extracellular matrix. Nature Protocols, 2016, 11, 2320-2327.	12.0	26
106	<i>In Vivo</i> Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 4764-4769.	3.2	44
107	The Extracellular Matrix of Fungal Biofilms. Advances in Experimental Medicine and Biology, 2016, 931, 21-35.	1.6	52
108	Intraluminal Release of an Antifungal β -Peptide Enhances the Antifungal and Anti-Biofilm Activities of Multilayer-Coated Catheters in a Rat Model of Venous Catheter Infection. ACS Biomaterials Science and Engineering, 2016, 2, 112-121.	5.2	29

#	ARTICLE	IF	CITATIONS
109	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, 409-417.	5.8	1,258
110	Targeting Fibronectin To Disrupt In Vivo <i>Candida albicans</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3152-3155.	3.2	18
111	Antifungal Agents. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 51-83.	5.1	264
112	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, e1-e50.	5.8	2,489
113	Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions. <i>PLoS Pathogens</i> , 2016, 12, e1005828.	4.7	93
114	Transcriptional rewiring over evolutionary timescales changes quantitative and qualitative properties of gene expression. <i>ELife</i> , 2016, 5, .	6.0	54
115	Fungal Biofilms: <i>In Vivo</i> Models for Discovery of Anti-Biofilm Drugs. <i>Microbiology Spectrum</i> , 2015, 3, .	3.0	49
116	Fungal Biofilms: <i>In Vivo</i> Models for Discovery of Anti-Biofilm Drugs. , 2015, , 33-49.		3
117	Histoplasmosis Complicating Tumor Necrosis Factor- α Blocker Therapy: A Retrospective Analysis of 98 Cases. <i>Clinical Infectious Diseases</i> , 2015, 61, 409-417.	5.8	111
118	Nontoxic antimicrobials that evade drug resistance. <i>Nature Chemical Biology</i> , 2015, 11, 481-487.	8.0	74
119	An expanded regulatory network temporally controls <i>Candida albicans</i> biofilm formation. <i>Molecular Microbiology</i> , 2015, 96, 1226-1239.	2.5	140
120	Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an <i>In Vivo</i> Murine Invasive Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1265-1272.	3.2	83
121	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1258-1264.	3.2	32
122	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). <i>Medical Mycology</i> , 2015, 53, 440-446.	0.7	79
123	Community participation in biofilm matrix assembly and function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4092-4097.	7.1	139
124	The synthesis of indolo[2,3-b]quinoline derivatives with a guanidine group: Highly selective cytotoxic agents. <i>European Journal of Medicinal Chemistry</i> , 2015, 105, 208-219.	5.5	43
125	<i>In Vivo</i> Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6568-6574.	3.2	13
126	Application of 3D NMR for Structure Determination of Peptide Natural Products. <i>Journal of Organic Chemistry</i> , 2015, 80, 8713-8719.	3.2	19

#	ARTICLE	IF	CITATIONS
127	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . Drug Resistance Updates, 2015, 21-22, 30-40.	14.4	262
128	Host Contributions to Construction of Three Device-Associated <i>Candida albicans</i> Biofilms. Infection and Immunity, 2015, 83, 4630-4638.	2.2	58
129	Development of New Strategies for Echinocandins: Progress in Translational Research. Clinical Infectious Diseases, 2015, 61, S601-S603.	5.8	6
130	Antifungal Pharmacokinetics and Pharmacodynamics. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a019653-a019653.	6.2	85
131	Pharmacodynamics of Quinolone Antimicrobial Agents. , 2014, , 147-155.		1
132	Comparative Phenotypic Analysis of the Major Fungal Pathogens <i>Candida parapsilosis</i> and <i>Candida albicans</i> . PLoS Pathogens, 2014, 10, e1004365.	4.7	108
133	A Histone Deacetylase Complex Mediates Biofilm Dispersal and Drug Resistance in <i>Candida albicans</i> . MBio, 2014, 5, e01201-14.	4.1	70
134	Novel Entries in a Fungal Biofilm Matrix Encyclopedia. MBio, 2014, 5, e01333-14.	4.1	234
135	Fungal Biofilms, Drug Resistance, and Recurrent Infection. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a019729-a019729.	6.2	196
136	Searching for new derivatives of neocryptolepine: Synthesis, antiproliferative, antimicrobial and antifungal activities. European Journal of Medicinal Chemistry, 2014, 78, 304-313.	5.5	29
137	Forazolineâ€¦A: Marineâ€¦Derived Polyketide with Antifungal Inâ€¦Vivo Efficacy. Angewandte Chemie - International Edition, 2014, 53, 11583-11586.	13.8	98
138	Rat Indwelling Urinary Catheter Model of <i>Candida albicans</i> Biofilm Infection. Infection and Immunity, 2014, 82, 4931-4940.	2.2	38
139	Epidemiology and Outcomes of Invasive Candidiasis Due to Non- <i>albicans</i> Species of <i>Candida</i> in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004â€“2008. PLoS ONE, 2014, 9, e101510.	2.5	338
140	The Role of Biofilm Matrix in Mediating Antifungal Resistance. , 2014, , 1-14.		0
141	Race and invasive fungal infection in solid organ transplant recipients. Ethnicity and Disease, 2014, 24, 382-5.	2.3	2
142	Mechanisms of <i>Candida</i> biofilm drug resistance. Future Microbiology, 2013, 8, 1325-1337.	2.0	317
143	Antifungal therapy: current concepts and evidence-based management. Current Medical Research and Opinion, 2013, 29, 289-290.	1.9	1
144	Posaconazole Pharmacodynamic Target Determination against Wild-Type and <i>Cyp51</i> Mutant Isolates of <i>Aspergillus fumigatus</i> in an <i>In Vivo</i> Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 579-585.	3.2	68

#	ARTICLE	IF	CITATIONS
145	Insights into fungal pathogenesis from the iatrogenic epidemic of <i>Exserohilum rostratum</i> fungal meningitis. <i>Fungal Genetics and Biology</i> , 2013, 61, 143-145.	2.1	17
146	Optimizing antifungal choice and administration. <i>Current Medical Research and Opinion</i> , 2013, 29, 13-18.	1.9	83
147	Regulatory Role of Glycerol in <i>Candida albicans</i> Biofilm Formation. <i>MBio</i> , 2013, 4, e00637-12.	4.1	77
148	Isavuconazole Pharmacodynamic Target Determination for <i>Candida</i> Species in an <i>In Vivo</i> Murine Disseminated Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5642-5648.	3.2	52
149	Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> at Inocula of 10^{10} and 10^7 CFU Injected into Opposite Thighs of Neutropenic Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1434-1441.	3.2	48
150	Impact of <i>In Vivo</i> Triazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy against <i>Cyp51</i> Mutant Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5438-5447.	3.2	29
151	Reply to Oude Lashof and Vogelaers. <i>Clinical Infectious Diseases</i> , 2013, 56, 1515-1516.	5.8	1
152	Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an <i>In Vivo</i> Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and <i>cyp51</i> Mutant Isolates of <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6284-6289.	3.2	78
153	Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5714-5716.	3.2	28
154	Preparation of <i>Candida albicans</i> Biofilms for Transmission Electron Microscopy. <i>Bio-protocol</i> , 2013, 3, .	0.4	4
155	Preparation of <i>Candida albicans</i> Biofilms Using an in vivo Rat Central Venous Catheter Model. <i>Bio-protocol</i> , 2013, 3, .	0.4	3
156	Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in <i>Aspergillus fumigatus</i> . <i>PeerJ</i> , 2013, 1, e4.	2.0	63
157	A <i>Candida</i> Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance. <i>PLoS Pathogens</i> , 2012, 8, e1002848.	4.7	240
158	Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2012, 54, 1110-1122.	5.8	649
159	Editorial Commentary: Antifungal Therapeutic Drug Monitoring Progress: Getting It Right the First Time. <i>Clinical Infectious Diseases</i> , 2012, 55, 391-393.	5.8	12
160	Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via <i>In Vivo</i> Pharmacodynamic Evaluation against <i>Candida glabrata</i> with and without <i>fls</i> Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5875-5882.	3.2	38
161	Comparative Pharmacodynamics of the New Oxazolidinone Tedizolid Phosphate and Linezolid in a Neutropenic Murine <i>Staphylococcus aureus</i> Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5916-5922.	3.2	49
162	A Recently Evolved Transcriptional Network Controls Biofilm Development in <i>Candida albicans</i> . <i>Cell</i> , 2012, 148, 126-138.	28.9	607

#	ARTICLE	IF	CITATIONS
163	Comparative analysis of Candida biofilm quantitation assays. Medical Mycology, 2012, 50, 214-218.	0.7	69
164	Modeling of Fungal Biofilms Using a Rat Central Vein Catheter. Methods in Molecular Biology, 2012, 845, 547-556.	0.9	17
165	Protein Binding: Do We Ever Learn?. Antimicrobial Agents and Chemotherapy, 2011, 55, 3067-3074.	3.2	212
166	Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting. Critical Care Clinics, 2011, 27, 123-147.	2.6	48
167	Optimizing a Candida Biofilm Microtiter Plate Model for Measurement of Antifungal Susceptibility by Tetrazolium Salt Assay. Journal of Clinical Microbiology, 2011, 49, 1426-1433.	3.9	127
168	Conserved and Divergent Roles of Bcr1 and CFEM Proteins in Candida parapsilosis and Candida albicans. PLoS ONE, 2011, 6, e28151.	2.5	76
169	Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity Regulation. Eukaryotic Cell, 2011, 10, 1660-1669.	3.4	139
170	Antifungal PK/PD Considerations in Fungal Pulmonary Infections. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 783-794.	2.1	22
171	Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia. Antimicrobial Agents and Chemotherapy, 2011, 55, 2113-2121.	3.2	102
172	Antifungal Pharmacokinetics and Pharmacodynamics. , 2011, , 121-134.		3
173	Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms. PLoS Pathogens, 2011, 7, e1002257.	4.7	231
174	Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in Candida dubliniensis. Eukaryotic Cell, 2011, 10, 803-819.	3.4	97
175	Comparison of In Vitro Susceptibility Characteristics of <i>Candida</i> Species from Cases of Invasive Candidiasis in Solid Organ and Stem Cell Transplant Recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. Journal of Clinical Microbiology, 2011, 49, 2404-2410.	3.9	51
176	Azoles. , 2011, , 61-93.		1
177	The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses. Current Infectious Disease Reports, 2010, 12, 471-478.	3.0	7
178	Role of Fks1p and Matrix Glucan in <i>Candida albicans</i> Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene. Antimicrobial Agents and Chemotherapy, 2010, 54, 3505-3508.	3.2	188
179	Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis. Clinical Infectious Diseases, 2010, 50, 1559-1567.	5.8	269
180	Genetic Basis of <i>Candida</i> Biofilm Resistance Due to Drug-Induced Sequestering Matrix Glucan. Journal of Infectious Diseases, 2010, 202, 171-175.	4.0	220

#	ARTICLE	IF	CITATIONS
181	Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001â€“2006: Overview of the Transplantâ€Associated Infection Surveillance Network (TRANSNET) Database. <i>Clinical Infectious Diseases</i> , 2010, 50, 1091-1100.	5.8	1,194
182	Development and Validation of an <i>In Vivo</i> <i>Candida albicans</i> Biofilm Denture Model. <i>Infection and Immunity</i> , 2010, 78, 3650-3659.	2.2	138
183	Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplantâ€Associated Infection Surveillance Network (TRANSNET). <i>Clinical Infectious Diseases</i> , 2010, 50, 1101-1111.	5.8	1,281
184	Biofilm Matrix Regulation by <i>Candida albicans</i> Zap1. <i>PLoS Biology</i> , 2009, 7, e1000133.	5.6	286
185	Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 24-34.	3.2	442
186	Voriconazole Use for Endemic Fungal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1648-1651.	3.2	130
187	Time Course Global Gene Expression Analysis of an <i>In Vivo</i> <i>Candida</i> Biofilm. <i>Journal of Infectious Diseases</i> , 2009, 200, 307-313.	4.0	156
188	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009, 48, 503-535.	5.8	2,644
189	Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy. <i>Current Fungal Infection Reports</i> , 2008, 2, 12-19.	2.6	1
190	Review of techniques for diagnosis of catheter-related <i>Candida</i> biofilm infections. <i>Current Fungal Infection Reports</i> , 2008, 2, 237-243.	2.6	4
191	Complementary Adhesin Function in <i>C. albicans</i> Biofilm Formation. <i>Current Biology</i> , 2008, 18, 1017-1024.	3.9	293
192	Synergistic Effect of Calcineurin Inhibitors and Fluconazole against <i>Candida albicans</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1127-1132.	3.2	205
193	Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3022-3028.	3.2	142
194	Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> with Inducible Clindamycin Resistance in Murine Thigh Infection and <i>In Vitro</i> Pharmacodynamic Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2156-2162.	3.2	91
195	Reduced Biocide Susceptibility in <i>Candida albicans</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3411-3413.	3.2	61
196	Therapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic Considerations. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 167-172.	2.0	136
197	<i>In Vivo</i> Pharmacodynamic Activity of the Glycopeptide Dalbavancin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1633-1642.	3.2	102
198	CNS pharmacokinetics of antifungal agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 573-581.	3.3	92

#	ARTICLE	IF	CITATIONS
199	Î²-1,3 Glucan as a Test for Central Venous Catheter Biofilm Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 1705-1712.	4.0	85
200	Putative Role of Î²-1,3 Glucans in <i>Candida albicans</i> Biofilm Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 510-520.	3.2	362
201	Pharmacokinetics and Pharmacodynamics of Tetracyclines. <i>Infectious Disease and Therapy</i> , 2007, , 267-278.	0.0	16
202	Antifungal Agents Pharmacokinetics and Pharmacodynamics of Amphotericin B. <i>Infectious Disease and Therapy</i> , 2007, , 315-326.	0.0	0
203	Pharmacology of Systemic Antifungal Agents. <i>Clinical Infectious Diseases</i> , 2006, 43, S28-S39.	5.8	253
204	Pharmacokinetics and Pharmacodynamics of Antifungals. <i>Infectious Disease Clinics of North America</i> , 2006, 20, 679-697.	5.1	92
205	<i>Candida albicans</i> biofilm development, modeling a host-pathogen interaction. <i>Current Opinion in Microbiology</i> , 2006, 9, 340-345.	5.1	190
206	Polymeric Micelles for the Delivery of Polyene Antibiotics. <i>ACS Symposium Series</i> , 2006, , 14-26.	0.5	1
207	Critical Role of Bcr1-Dependent Adhesins in <i>C. albicans</i> Biofilm Formation In Vitro and In Vivo. <i>PLoS Pathogens</i> , 2006, 2, e63.	4.7	443
208	Imaging of the Development and Therapeutic Response of an In Vivo Fungal Catheter Biofilm. <i>Microscopy Today</i> , 2005, 13, 30-33.	0.3	0
209	Use of an Animal Model of Disseminated Candidiasis in the Evaluation of Antifungal Therapy. , 2005, 118, 111-128.		21
210	The Microbe-Host Interface in Respiratory Tract Infections Edited by Jan L. L. Kimpen and Octavio Ramilo Wymondham, UK: Horizon Bioscience, 2005. 323 pp., illustrated. \$139.95 (cloth). <i>Clinical Infectious Diseases</i> , 2005, 41, 767-768.	5.8	0
211	In Vivo Pharmacodynamic Activity of Daptomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 63-68.	3.2	342
212	Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. <i>Clinics in Laboratory Medicine</i> , 2004, 24, 477-502.	1.4	79
213	Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. <i>Drug Resistance Updates</i> , 2004, 7, 185-194.	14.4	17
214	Clinical utility of antifungal pharmacokinetics and pharmacodynamics. <i>Current Opinion in Infectious Diseases</i> , 2004, 17, 533-540.	3.1	41
215	Clinical pharmacodynamics of antifungals. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 635-649.	5.1	27
216	In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1179-1186.	3.2	154

#	ARTICLE	IF	CITATIONS
217	Treatment of Community-Acquired Respiratory Tract Infections with Other Antibiotics. , 2003, , 145-153.		0
218	Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. Current Opinion in Investigational Drugs, 2003, 4, 991-8.	2.3	9
219	Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo. Antimicrobial Agents and Chemotherapy, 1999, 43, 2473-2478.	3.2	66
220	Pharmacodynamics of Fluoroquinolones in Experimental Models of Endocarditis. Clinical Infectious Diseases, 1998, 27, 47-50.	5.8	56
221	Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatric Infectious Disease Journal, 1996, 15, 255-259.	2.0	425
222	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. , 0, , 343-371.		3